A phase II study to evaluate the efficacy of regorafenib in C-KIT mutated metastatic malignant melanoma patients who have progressed on first-line treatment: A Multicenter Trial of Korean Cancer Study Group (UN-14–13)

K. H. Kim; H. J. Lee; S. J. Lee; M. Kim; M. S. Ahn; M. Y. Choi; N. R. Lee; M. Jung; S. J. Shin

doi:10.1016/S0959-8049(22)01025-5

A phase II study to evaluate the efficacy of regorafenib in C-KIT mutated metastatic malignant melanoma patients who have progressed on first-line treatment: A Multicenter Trial of Korean Cancer Study Group (UN-14–13)

K. H. Kim
, H. J. Lee
, S. J. Lee
, M. Kim
, M. S. Ahn
, M. Y. Choi
, N. R. Lee
, M. Jung
, S. J. Shin

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	S85-S86
Journal	European Journal of Cancer
Volume	174
DOIs	https://doi.org/10.1016/S0959-8049(22)01025-5
State	Published - Oct 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0959-8049(22)01025-5

Cite this

Kim, K. H., Lee, H. J., Lee, S. J., Kim, M., Ahn, M. S., Choi, M. Y., Lee, N. R., Jung, M., & Shin, S. J. (2022). A phase II study to evaluate the efficacy of regorafenib in C-KIT mutated metastatic malignant melanoma patients who have progressed on first-line treatment: A Multicenter Trial of Korean Cancer Study Group (UN-14–13). European Journal of Cancer, 174, S85-S86. https://doi.org/10.1016/S0959-8049(22)01025-5

@article{3be2aca6b6f04d01ac1d49ae3b0c7d94,

title = "A phase II study to evaluate the efficacy of regorafenib in C-KIT mutated metastatic malignant melanoma patients who have progressed on first-line treatment: A Multicenter Trial of Korean Cancer Study Group (UN-14–13)",

author = "Kim, \{K. H.\} and Lee, \{H. J.\} and Lee, \{S. J.\} and M. Kim and Ahn, \{M. S.\} and Choi, \{M. Y.\} and Lee, \{N. R.\} and M. Jung and Shin, \{S. J.\}",

year = "2022",

month = oct,

doi = "10.1016/S0959-8049(22)01025-5",

language = "English",

volume = "174",

pages = "S85--S86",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd.",

}

Kim, KH, Lee, HJ, Lee, SJ, Kim, M, Ahn, MS, Choi, MY, Lee, NR, Jung, M & Shin, SJ 2022, 'A phase II study to evaluate the efficacy of regorafenib in C-KIT mutated metastatic malignant melanoma patients who have progressed on first-line treatment: A Multicenter Trial of Korean Cancer Study Group (UN-14–13)', European Journal of Cancer, vol. 174, pp. S85-S86. https://doi.org/10.1016/S0959-8049(22)01025-5

A phase II study to evaluate the efficacy of regorafenib in C-KIT mutated metastatic malignant melanoma patients who have progressed on first-line treatment: A Multicenter Trial of Korean Cancer Study Group (UN-14–13). / Kim, K. H.; Lee, H. J.; Lee, S. J. et al.
In: European Journal of Cancer, Vol. 174, 10.2022, p. S85-S86.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - A phase II study to evaluate the efficacy of regorafenib in C-KIT mutated metastatic malignant melanoma patients who have progressed on first-line treatment

T2 - A Multicenter Trial of Korean Cancer Study Group (UN-14–13)

AU - Kim, K. H.

AU - Lee, H. J.

AU - Lee, S. J.

AU - Kim, M.

AU - Ahn, M. S.

AU - Choi, M. Y.

AU - Lee, N. R.

AU - Jung, M.

AU - Shin, S. J.

PY - 2022/10

Y1 - 2022/10

UR - https://www.scopus.com/pages/publications/85144017787

U2 - 10.1016/S0959-8049(22)01025-5

DO - 10.1016/S0959-8049(22)01025-5

M3 - Article

AN - SCOPUS:85144017787

SN - 0959-8049

VL - 174

SP - S85-S86

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -